SCYNEXIS
Durham
About SCYNEXIS
SCYNEXIS, Inc. operates as a drug discovery and development company in the United States and internationally. It engages in drug discovery, development, and manufacturing projects in various areas, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The company offers SCY-635, a drug that is used for patients who are chronically infected with genotype 1 hepatitis C virus. It also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is based in Durham, North Carolina.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $319.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:SCYX
- Website: scynexis.com
- Phone: +1 9195448697
Industries & Categories
Biotechnology, Health Care, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/scynexis-63893 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.